The Contribution of Multinational Pharmaceutical Companies in the Development of Pakistan Economy
PRESENTATION ANALYSIS AND INTERPRETATION OF DATA
Major Therapeutic Categories
Antibiotics, vitamins and analgesics are the top three therapeutic classes in terms of sales by value. Anti-biotic dominate the market with approximately 24% of the market value. Vitamins and analgesics account for 6.6% and 6% of the market respectively. The vitamins and antibiotics sectors are vital not only because of their large size but also because of their astronomical growth. Sales of antibiotics are growing at 30% per year, while the growth rate in the vitamins segment is 20%.
The importance of vitamins in the domestic market is compounded by the fact that being nonessential drugs, their prices are now deregulated. This price deregulation, which occurred in 1993 has enhanced the competition within this therapeutic strata of the market and has placed companies like Abbot, Cyanamid, Pfizer, Sandoz, Squibb and Roche in a privileged position. Well-positioned competitors in the antibiotic arena include Smith Kline, Wyeth Squibb, Sandoz, Pfizer and Wellcome.
Seprtan, Amoxil and Ampiclox are three largest selling products in Pakistan. Wellcome produces Septran, whereas the other two are Beecham’s products. The sales of each of these three products are approximately $6 million to $9 million, larger than the total sales of many medium sized companies in the pharmaceutical industry in Pakistan.
The following table shows the value sales of the top 10 products:
Table 2:
THE VALUE SALES OF THE TOP 10 PRODUCTS
| | |
|PRODUCT |ESTIMATED SALES 1993 (RS. MN) |
|Septran (Wellcome) |272 - 290 |
|Amoxil (Beecham) |250 - 270
Major Therapeutic Categories
Antibiotics, vitamins and analgesics are the top three therapeutic classes in terms of sales by value. Anti-biotic dominate the market with approximately 24% of the market value. Vitamins and analgesics account for 6.6% and 6% of the market respectively. The vitamins and antibiotics sectors are vital not only because of their large size but also because of their astronomical growth. Sales of antibiotics are growing at 30% per year, while the growth rate in the vitamins segment is 20%.
The importance of vitamins in the domestic market is compounded by the fact that being nonessential drugs, their prices are now deregulated. This price deregulation, which occurred in 1993 has enhanced the competition within this therapeutic strata of the market and has placed companies like Abbot, Cyanamid, Pfizer, Sandoz, Squibb and Roche in a privileged position. Well-positioned competitors in the antibiotic arena include Smith Kline, Wyeth Squibb, Sandoz, Pfizer and Wellcome.
Seprtan, Amoxil and Ampiclox are three largest selling products in Pakistan. Wellcome produces Septran, whereas the other two are Beecham’s products. The sales of each of these three products are approximately $6 million to $9 million, larger than the total sales of many medium sized companies in the pharmaceutical industry in Pakistan.
The following table shows the value sales of the top 10 products:
Table 2:
THE VALUE SALES OF THE TOP 10 PRODUCTS
| | |
|PRODUCT |ESTIMATED SALES 1993 (RS. MN) |
|Septran (Wellcome) |272 - 290 |
|Amoxil (Beecham) |250 - 270